Drug Discovery

Novotech Acquires US-based Drug Development Consulting Firm, CBR International

Novotech, the leading Asia Pacific centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversi...

 January 12, 2023 | News

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization o...

 January 11, 2023 | News

ProPharma Group launches revolutionary new operating model to deliver life-saving drugs, medical devices and diagnostics to market faster

ProPharma Group – the end-to-end, global provider of regulatory, clinical and compliance services for the pharmaceutical, biotechnology and medical d...

 January 10, 2023 | News

FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and Drug...

 January 09, 2023 | News

Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US

Fosun Pharma will have the right to commercialise serplulimab upon approval in the US, and Henlius will retain responsibility for development, manufacturin...

 January 09, 2023 | News

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug co...

 January 04, 2023 | News

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

This submission is based on data from the confirmatory Phase 2 clinical study CARTIFAN-1 (NCT03758417) conducted in China, which evaluated the efficacy and...

 January 03, 2023 | News

The Best of 2022: FDA Approvals and the Breakthroughs That Enabled Them

For a field like cancer research, in which progress can sometimes appear to happen slowly, it is especially important to remind ourselves of the crucial ad...

 December 31, 2022 | News | By Calley Jones, PhD

GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development

According to the collaboration agreements, WuXi XDC will actively promote GeneQuantum’s proprietary iLDC (intelligent Ligase-dependent Conjugation) a...

 December 28, 2022 | News

Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008

The trial is an open-label, dose-escalation study (No. YH008101) that will evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor a...

 December 21, 2022 | News

STADA partners with BIAL to bring Ongentys to Parkinson’s patients in Australia

STADA receives from BIAL exclusive rights to market and distribute Ongentys (opicapone) capsules in Australia STADA Specialty Head Bryan Kim: "Ongentys ...

 December 19, 2022 | News

Janssen Submits Biologics License Application to U.S. FDA

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and ...

 December 12, 2022 | News

Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient tr...

 December 09, 2022 | News

FDA grants ODD for new NK treatment

The US FDA has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye diseas...

 December 08, 2022 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close